Custom VHH Discovery Service: A Guide to Workflow, Deliverables, and Project Scope

A custom VHH discovery service is a project-based route to identifying and evaluating single-domain antibody candidates against a buyer-defined target. A typical engagement may include target and antigen review, candidate generation, screening, sequence identification, and agreed validation or production. The exact workflow and final deliverables depend on the discovery platform, target biology, and intended use. For veterinary medicine projects, we recommend defining the species, sample type, and end-use assay before requesting a proposal.

Please visit our website for more information on this topic.

At NBbiolab, we encourage buyers to treat discovery as a scoped research project rather than a guaranteed route to a particular performance outcome. The most useful first step is to share the target, available antigen materials, application, and decision criteria. This guide explains what to clarify, what deliverables to request, and how to compare service proposals.

Who This Guide Is For

This guide is for pharmaceutical, diagnostic, animal-health, and research teams considering custom VHH discovery. It is also relevant to buyers who need a veterinary assay reagent but are unsure whether to purchase an existing binder or commission a new discovery project. The workflow below is a planning framework; each provider may use different methods and offer different service boundaries.

What a Custom VHH Discovery Project Covers

Basic concept

VHHs are antibody-derived binding domains that can be selected or generated to recognize a specified target. A VHH domain is commonly described as approximately 12–15 kDa, although the exact molecular mass depends on its sequence and any added tags or fusion partners. Their compact format can be useful when designing research reagents and assay components, but it does not by itself establish affinity, specificity, stability, or suitability for a particular veterinary application.

Possible discovery approaches and materials

Depending on the provider’s platform, discovery may use an immunized-animal source, a synthetic or naïve library, or another selection approach. Each route has different requirements and should be discussed explicitly rather than assumed from the phrase “custom VHH discovery.” The project may also involve recombinant expression and purification, but buyers should confirm whether these are included, optional, or separately quoted.

Antigen format is a key project input. Providers may ask for purified protein, a defined protein domain, cells displaying a membrane target, or another biologically relevant presentation. For veterinary targets, confirm that the antigen sequence and conformation represent the species and strain relevant to the intended use; a binder to one recombinant fragment may not recognize the target in a different biological context.

Typical Workflow and Project Decisions

1. Define the target and intended use

Start with the target name, species, sequence or accession information, and biological context. State whether the VHH is intended for an ELISA, lateral-flow assay, immunohistochemistry, cell-based research, or another use. If the goal is detection in animal samples, identify the sample matrix—such as serum, plasma, milk, or tissue—and any known interference concerns.

2. Review antigen readiness

Ask the provider to review antigen quantity, purity information, buffer, storage history, and relevant controls before the project begins. For membrane proteins, conformational epitopes, or targets with post-translational modifications, discuss whether the supplied antigen is representative of the native target. If there is uncertainty, consider agreeing on an antigen qualification step before committing to the full discovery scope.

3. Select the discovery and screening strategy

The provider and buyer should agree on the discovery route, screening format, and criteria for advancing candidates. These criteria may include target binding, binding to a related species variant, lack of binding to selected off-targets, or recognition in a functional assay. A binding signal in one screening format is a candidate-selection result, not proof of diagnostic performance or therapeutic activity.

NBbiolab Product Page

4. Identify and characterize candidates

Depending on the quoted scope, shortlisted candidates may be sequenced, expressed, purified, and evaluated in one or more assays. Request clarity on the number of candidates delivered, the format and amount of material, and which characterization data will accompany each candidate. As a planning example—not a universal requirement—buyers can discuss whether 0.1–1 mg of purified material per lead is appropriate for their initial assay development.

5. Validate for the intended application

Validation should reflect how the VHH will actually be used. A veterinary diagnostic project may require testing in the relevant sample matrix and against representative target variants, while a research reagent project may prioritize reproducible binding and documented identity. Agree in advance on what counts as a pass, what controls are needed, and whether application-specific validation is included or reserved for a follow-on phase.

Deliverables to Define in the Proposal

“Discovery complete” can mean different things across suppliers, so request a written deliverables list. Depending on scope, it may include candidate sequences, screening and characterization data, purified VHH samples, expression or purification details, and recommendations for next-stage testing. Also confirm whether raw data, assay protocols, negative-control results, and repeat testing are included.

How to Match Scope to a Veterinary Application

For a research reagent, a project may focus on sequence identification and binding confirmation. For an assay-development program, add application-relevant testing, such as recognition of the target in the intended matrix and assessment against likely cross-reactants. For a therapeutic or functional research concept, binding alone is insufficient; the project may require additional functional studies and a separate development plan.

Initial assay conditions should be treated as experimental variables. For example, an assay developer might evaluate a VHH across an illustrative 0.1–10 µg/mL concentration range during early titration, then optimize based on signal, background, and assay format. This is a starting range for discussion, not a guaranteed optimal condition or a specification for any particular candidate.

Pricing, Minimums, and Lead Time

Custom discovery pricing depends on factors such as target complexity, antigen readiness, discovery platform, screening depth, number of candidates, validation assays, and requested production quantity. Minimum order quantities may apply to expression or purification services, but they are provider- and format-specific. Request a quote that separates core discovery from optional validation and scale-up so you can compare proposals on equivalent scope.

Lead time should be quoted by project stage, with assumptions and buyer dependencies stated. Antigen delivery, sequence confirmation, assay development, and review of results can affect the schedule. Rather than relying on a generic timeline, ask which milestones require your approval and how changes to the target or assay plan would affect cost and timing.

Supplier Evaluation Checklist

• Does the supplier explain its discovery platform and the inputs required from you?
• Are screening assays, candidate advancement criteria, and deliverables defined in writing?
• Can the proposed validation reflect your veterinary species, sample matrix, and intended use?
• Are sequence ownership, usage rights, confidentiality, and follow-on production addressed?
• Does the proposal distinguish confirmed capabilities from optional or out-of-scope work?

At NBbiolab, we recommend sharing your target information and application requirements early so the project scope can be discussed before a quotation is finalized. We can review the requested discovery, characterization, and material-supply needs with you and clarify which items should be included in the proposed scope. Project-specific methods, deliverables, timelines, and commercial terms should be confirmed directly in the quotation and agreement.

Key Takeaways and Next Steps

• A custom VHH discovery service is a scoped workflow, not a single standardized deliverable.
• Antigen quality, species relevance, screening criteria, and intended use shape project fit.
• Ask for a written breakdown of discovery, validation, candidate data, material supply, rights, price, and timing.
• For veterinary applications, plan validation around the relevant species and sample matrix rather than relying on binding data alone.

In short, a custom VHH project is most useful when its workflow and acceptance criteria are aligned with the intended application from the start. Prepare your target details, antigen information, assay goal, and preferred deliverables before approaching suppliers. Contact NBbiolab to discuss your project requirements and request a scope that clearly separates discovery from optional validation and follow-on production.